Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366465 | 0.82 | BRAF (0.49) | BRAFSCN8ASCN10A | |
| SCHEMBL1366468 | 0.80 | SCN8A (0.50) | BRAFSCN8ASCN10A | |
| SCHEMBL4106117 | 0.80 | BRAF (0.54) | BRAF | |
| SCHEMBL1368279 | 0.78 | BRAF (0.55) | BRAF | |
| SCHEMBL31171386 | 0.78 | BRAF (0.54) | BRAFSCN8ASCN10ACDK8 | |
| SCHEMBL1369149 | 0.78 | MEN1 (0.49) | BRAF | |
| SCHEMBL1365192 | 0.78 | BRAF (0.46) | BRAF | |
| SCHEMBL1367368 | 0.77 | BRAF (0.44) | BRAFNTRK1 | |
| SCHEMBL1366699 | 0.75 | CYP1A2 (0.52) | BRAF | |
| SCHEMBL1366444 | 0.75 | BRAF (0.52) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| CN-101511828-A | Heteroaryl derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | claimed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | claimed |
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| CN-101511828-A | Heteroaryl derivatives as protein kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | BRAF 35/4885NTRK1 1448/4885NTRK2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.